July 6, 2009 4:20 PM
- Text
Sepracor Tested Sleeping Pill Lunesta on Kids
(MoneyWatch) The FDA stopped two clinical trials run by Sepracor studying sleeping pill Lunesta in children. The July 4 weekend is traditionally one of those times when companies drop bad news into the media in the hopes that America will be too busy eating and drinking to notice. This year was no exception as Sepracor unveiled this release, which states that a trial of its new depression candidate failed and oh, by the way, our sleeping-pills-for-kids experiments have been stopped, too. The statement said:
The math suggests one of these trials is still under way. If you really want to scare yourself regarding the amibitions Sepracor has for Lunesta, do a search for the brand name. It brings up 48 different tests for unapproved indications as varied as use in patients with Parkinson's Disease, shift workers, schizophrenia, cancer and low back pain.
Hat tip to Internet Drug News.
It is not clear exactly what is being studied. But ClinicalTrials.gov lists these three trials of Lunesta in kids. One for "Children and Adolescents With Attention-Deficit/Hyperactivity Disorder - Associated Insomnia," a second for the long-term safety effects in the same condition, and a third to see whether kids recovering from burns get better sleep with Lunesta or Takeda's Rozerem.In April 2009, Sepracor initiated two additional pediatric studies in accordance with the FDA's Written Request. The FDA has notified us that these two studies have been put on clinical hold due to its concerns regarding non-clinical data that could be relevant to the administration of eszopiclone in children. The clinical hold does not relate to any findings observed in the pediatric clinical studies...
The math suggests one of these trials is still under way. If you really want to scare yourself regarding the amibitions Sepracor has for Lunesta, do a search for the brand name. It brings up 48 different tests for unapproved indications as varied as use in patients with Parkinson's Disease, shift workers, schizophrenia, cancer and low back pain.
Hat tip to Internet Drug News.
- Previously:
- End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight
- Sepracor CEO Got 44% Raise as He Planned 940 Layoffs
- Sanofi, Sepracor Keep Local Politicians in Thrall Over Taxes
- Insomnia and Antidepressant Sales Give Lie to DTC Myths
- Lilly, Barr, AZ and Sepracor Were Generous to Sen. Hatch's Utah Charity
- Sepracor Announces 940 Layoffs; Achieves the Impossible on Lunesta Sales
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook
on CBS News
- Dad of NYC subway bomb plotter gets prison time
- NH 14-year-old shoots self in face in cafeteria
- Ginsburg questions 1973 abortion ruling's timing
- AG: Pa. man's Facebook 'surfer' page lured teens
on Facebook
- Adele sings a cappella for Anderson Cooper
- Josh Powell had "incestuous" images on his home computer, authorities say
on CBS News







